BridgeBio Pharma, Inc.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Net product revenue | $253,346 | $108,111 | $656,382 | $216,351 |
| License and services revenue | 79,314 | 8,311 | 89,537 | 125,441 |
| Royalty revenue | 20,511 | 4,278 | 45,443 | 6,106 |
| Total revenues, net | 353,171 | 120,700 | 791,362 | 347,898 |
| Operating costs and expenses: | ||||
| Cost of revenues: | ||||
| Cost of goods sold | 12,317 | 4,028 | 30,577 | 8,910 |
| Cost of license, services, and royalty revenue | 8,133 | 2,535 | 14,858 | 3,945 |
| Total cost of revenues | 20,450 | 6,563 | 45,435 | 12,855 |
| Research and development | 143,506 | 112,874 | 419,590 | 335,536 |
| Selling, general and administrative | 200,854 | 137,621 | 551,011 | 373,140 |
| Restructuring, impairment, and related charges | — | 8,841 | — | 10,216 |
| Total operating costs and expenses | 364,810 | 265,899 | 1,016,036 | 731,747 |
| Loss from operations | (11,639) | (145,199) | (224,674) | (383,849) |
| Other income (expense), net: | ||||
| Interest income | 13,105 | 6,239 | 26,010 | 15,522 |
| Interest expense | (13,255) | (11,739) | (39,475) | (41,467) |
| Noncash interest expense on deferred royalty obligations (1) | (42,282) | (36,410) | (123,500) | (86,460) |
| Net loss from equity method investments | (7,312) | (15,834) | (32,030) | (51,579) |
| Loss on extinguishment of debt | — | — | — | (21,155) |
| Other income, net | 2,116 | 16,461 | 11,956 | 31,240 |
| Total other expense, net | (47,628) | (41,283) | (157,039) | (153,899) |
| Loss before income taxes | (59,267) | (186,482) | (381,713) | (537,748) |
| Provision for (benefit from) income taxes | 1,229 | (1,545) | 1,229 | 555 |
| Net loss | (60,496) | (184,937) | (382,942) | (538,303) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 3,786 | 2,194 | 9,973 | 6,235 |
| Net loss attributable to BridgeBio | (56,710) | (182,743) | (372,969) | (532,068) |
| Preferred stock dividends and accretion | 26,293 | — | 26,293 | — |
| Net loss attributable to common stockholders of BridgeBio | $(83,003) | $(182,743) | $(399,262) | $(532,068) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.42) | $(0.95) | $(2.04) | $(2.79) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 196,029,851 | 191,854,152 | 195,539,752 | 190,845,133 |
(1)Including related party amounts of $(2,942) and $(13,878) for the period from July 1, 2026 to August 16, 2026 and for the period from January 1, 2026 to August 16, 2026, respectively, and $(5,383) and $(5,560) for the three and nine months ended September 30, 2025, respectively (as described in Note 9).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.